- Home
- PHVS vs CGEM Comparison
PHVS vs CGEM Comparison
Compare PHVS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- CGEM
- Stock Information
- Founded
- PHVS 2015
- CGEM 2016
- Country
- PHVS Netherlands
- CGEM United States
- Employees
- PHVS N/A
- CGEM N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- CGEM Health Care
- Exchange
- PHVS Nasdaq
- CGEM Nasdaq
- Market Cap
- PHVS 1.0B
- CGEM 955.5M
- IPO Year
- PHVS 2021
- CGEM 2021
- Fundamental
- Price
- PHVS $22.29
- CGEM $12.54
- Analyst Decision
- PHVS Buy
- CGEM Strong Buy
- Analyst Count
- PHVS 6
- CGEM 7
- Target Price
- PHVS $35.67
- CGEM $31.67
- AVG Volume (30 Days)
- PHVS 67.6K
- CGEM 547.8K
- Earning Date
- PHVS 11-13-2024
- CGEM 11-07-2024
- Dividend Yield
- PHVS N/A
- CGEM N/A
- EPS Growth
- PHVS N/A
- CGEM N/A
- EPS
- PHVS N/A
- CGEM N/A
- Revenue
- PHVS N/A
- CGEM N/A
- Revenue This Year
- PHVS N/A
- CGEM N/A
- Revenue Next Year
- PHVS N/A
- CGEM N/A
- P/E Ratio
- PHVS N/A
- CGEM N/A
- Revenue Growth
- PHVS N/A
- CGEM N/A
- 52 Week Low
- PHVS $15.37
- CGEM $7.64
- 52 Week High
- PHVS $33.00
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- PHVS 54.95
- CGEM 31.78
- Support Level
- PHVS $18.81
- CGEM $12.04
- Resistance Level
- PHVS $21.85
- CGEM $17.50
- Average True Range (ATR)
- PHVS 1.44
- CGEM 1.12
- MACD
- PHVS -0.17
- CGEM -0.36
- Stochastic Oscillator
- PHVS 52.81
- CGEM 9.15
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.